Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed relapsed/refractory non-Hodgkin lymphoma (NHL) with any of the following T-cell histologies:

  • Peripheral T-cell NHL (PTCL) not otherwise specified (NOS)
  • Anaplastic large cell T-cell lymphoma (ALCL) that is anaplastic lymphoma kinase either positive or negative
  • Angioimmunoblastic T-cell NHL
  • Subcutaneous panniculitis-like T-cell lymphoma
  • Enteropathy-associated T-cell NHL
  • Hepatosplenic T-cell lymphomas
  • Extranodal NK/T-cell lymphoma, nasal type
  • Adult T-cell leukemia/lymphoma
  • Unclassifiable PTCL
  • Transformed cutaneous T-cell lymphoma (CTCL) to PTCL with systemic involvement (not local skin transformation)
  • No other histologies are eligible; examples of ineligible histologies include: T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, NK-cell leukemia, mycosis fungoides, Sezary syndrome, lymphomatoid papulosis, and primary CTCL
• Patients must have received at least one course of prior systemic therapy which may include chemotherapy, antibody therapy, or immunotherapy; for all forms of systemic therapy, patients must have completed therapy at least 21 days prior to registration; patients must not be within 84 days of radioimmunotherapy; steroids at a low dose for control of itching (up to the equivalent of 20 mg of prednisone daily) are allowed
• Adequate sections and a paraffin block from the relapsed/refractory specimen must be submitted for review by the lymphoma pathology group; an adequate biopsy requires sufficient tissue to establish the architecture and a Revised European American Lymphoma (REAL) or World Health Organization (WHO) histologic subtype with certainty; thus, core biopsies, especially multiple core biopsies MAY be adequate; whereas, needle aspirations or cytologies are not adequate

• Patients must have bidimensionally measurable disease

  • Patients who also have non-measurable disease in addition to measurable disease must have all non-measurable disease assessed within 42 days prior to registration
• Patients must have a bilateral or unilateral bone marrow aspirate and biopsy performed within 42 days prior to registration
• Patients must not have clinical evidence of central nervous system involvement by lymphoma
• Patients must be able to swallow tablets
• Patients known to be human immunodeficiency virus (HIV)-positive must not have multi-drug resistant HIV infection, CD4 counts < 150/mcL, or other concurrent acquired immunodeficiency syndrome (AIDS)-defining conditions
• Absolute granulocyte count >= 1,000 cells/mcL
• Platelet count >= 75,000 cells/mcL (patients with documented marrow involvement may be transfused to this value)
• Serum bilirubin =< 2 times institutional upper limit of normal
• Patients must have a Zubrod performance status of 0, 1, or 2
• No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
• Pregnant or nursing women may not participate
• Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
• Patients may have received prior radiation in combination with systemic therapy; patients must not be within 21 days of external-beam radiation therapy
• Patients must not have received a previous allogeneic stem cell transplant or be within 90 days of an autologous stem cell transplant